Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000899243-19-019342)

Filing Details

Accession Number:: 0000899243-19-019342
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-08 21:32:17
Reporting Period:: 2019-07-03

Accepted Time:: 2019-07-08 21:32:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1621788	J. Ali Satvat	C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2550 San Francisco CA 94104		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-03	882,353	$29.90	24,575,501	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote

Footnotes

The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.